Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS -0.88%56 Return-on-Tangible-Asset is 6.90% as of Mar. 2026, which is 42% below its 10-year median of 11.99. GuruFocus rates NSE:REMUS with a GF Score™ of 56/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 120 Medical Distribution companies, Remus Pharmaceuticals ranks better than 84.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Remus Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹390 Mil. Remus Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was ₹5,645 Mil. Therefore, Remus Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 6.90%.
The historical rank and industry rank for Remus Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
NSE:REMUS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.15 Med: 11.99 Max: 25.12
Current: 7.15
During the past 7 years, Remus Pharmaceuticals's highest Return-on-Tangible-Asset was 25.12%. The lowest was 7.15%. And the median was 11.99%.
NSE:REMUS's Return-on-Tangible-Asset is ranked better than 84.17% of 120
companies
in the Medical Distribution industry
Industry Median: 2.305
vs NSE:REMUS: 7.15
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Remus Pharmaceuticals Return-on-Tangible-Asset Related Terms
Remus Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, COR, CAH: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.90% mean?
Remus Pharmaceuticals (NSE:REMUS) has a Return-on-Tangible-Asset of 6.90% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Remus Pharmaceuticals and its competitors. This is 42% below median its historical median of 11.99. Over the past decade, Remus Pharmaceuticals' Return-on-Tangible-Asset has ranged from 7.15 to 25.12. According to the industry distribution chart, Remus Pharmaceuticals ranks #19 out of 120 companies in the Medical Distribution industry, placing it in the top 15.8%.
Is Remus Pharmaceuticals' Return-on-Tangible-Asset too high?
Remus Pharmaceuticals' current Return-on-Tangible-Asset of 6.90% is 42% below median its 10-year median of 11.99. Over the past 10 years, this metric has ranged from a low of 7.15 to a high of 25.12. The Medical Distribution industry median Return-on-Tangible-Asset is 2.31. Remus Pharmaceuticals' value of 6.90% is 199.3% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #19 out of 120 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Return-on-Tangible-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #19 out of 120 companies for Return-on-Tangible-Asset. This places Remus Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.31. Remus Pharmaceuticals' value of 6.90% is 199.3% above this benchmark. Historically, Remus Pharmaceuticals' own Return-on-Tangible-Asset has ranged from 7.15 to 25.12 over the past decade. While the company's 10-year median is 11.99 vs. the industry median of 2.31, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.31, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Return-on-Tangible-Asset of 6.90% is 199.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Return-on-Tangible-Asset is 6.90%, which is 42% below median its own 10-year median of 11.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹714.65 — trading 65.5% below its estimated fair value. The current Return-on-Tangible-Asset is 6.90%, which is 42% below median its 10-year median of 11.99 and 199.3% above the Medical Distribution industry median of 2.31. Remus Pharmaceuticals' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Return-on-Tangible-Asset is 6.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹714.65 is trading 65.5% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Return-on-Tangible-Asset: 6.90% (42% below median its 10-year median of 11.99)
GF Value™: ₹2,071.36 vs. price of ₹714.65 (65.5% below fair value)
Industry Position: 199.3% above the Medical Distribution median (#19 of 120)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
56GF Score
Get the complete analysis for NSE:REMUS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
